LMTK3 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "LMTK3" in English language version.

refsWebsite

Global rank English rank

27nih.gov

4^th place

17doi.org

2^nd place

5semanticscholar.org

11^th place

8^th place

2ensembl.org

1,626^th place

1,007^th place

1sussex.ac.uk

6,651^st place

4,464^th place

1nii.ac.jp

304^th place

1,952^nd place

1worktribe.com

low place

1handle.net

102^nd place

76^th place

1harvard.edu

18^th place

17^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Ditsiou A, Gagliano T, Samuels M, Vella V, Tolias C, Giamas G (September 2021). "The multifaceted role of lemur tyrosine kinase 3 in health and disease". Open Biology. 11 (9) 210218. doi:10.1098/rsob.210218. PMC 8478525. PMID 34582708.
Wendler F, Purice TM, Simon T, Stebbing J, Giamas G (September 2021). "The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis" (PDF). Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (9) 165372. doi:10.1016/j.bbadis.2018.12.023. PMID 30597196.
Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D, et al. (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID 21602804. S2CID 5279914.
Fazi B, Felsani A, Grassi L, Moles A, D'Andrea D, Toschi N, et al. (September 2015). "The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors". Oncotarget. 6 (26): 22526–22552. doi:10.18632/oncotarget.4151. PMC 4673180. PMID 26188123.
Xu Z, Qi X, Zhang X, Yu L (May 2014). "Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer". Tumour Biology. 35 (5): 5007–5011. doi:10.1007/s13277-014-1660-3. PMID 24510346. S2CID 14656556.
Lu L, Yuan X, Zhang Q, Zhang H, Shen B (April 2017). "LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer". Molecular Medicine Reports. 15 (4): 2015–2022. doi:10.3892/mmr.2017.6262. PMC 5364963. PMID 28260052.
Jiang T, Lu X, Yang F, Wang M, Yang H, Xing N (October 2020). "LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway". FEBS Open Bio. 10 (10): 2107–2121. doi:10.1002/2211-5463.12964. PMC 7530379. PMID 32865871.
Kawa S, Fujimoto J, Tezuka T, Nakazawa T, Yamamoto T (March 2004). "Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling". Genes to Cells. 9 (3): 219–232. doi:10.1111/j.1356-9597.2004.00714.x. PMID 15005709.
Inoue T, Hoshina N, Nakazawa T, Kiyama Y, Kobayashi S, Abe T, et al. (April 2014). "LMTK3 deficiency causes pronounced locomotor hyperactivity and impairs endocytic trafficking". The Journal of Neuroscience. 34 (17): 5927–5937. doi:10.1523/JNEUROSCI.1621-13.2014. PMC 6608282. PMID 24760852.
Montrose K, Kobayashi S, Manabe T, Yamamoto T (August 2019). "Lmtk3-KO Mice Display a Range of Behavioral Abnormalities and Have an Impairment in GluA1 Trafficking". Neuroscience. 414: 154–167. doi:10.1016/j.neuroscience.2019.06.033. PMID 31310731. S2CID 195937172.
Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, et al. (April 2012). "LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome". Breast Cancer Research and Treatment. 132 (2): 537–544. doi:10.1007/s10549-011-1622-z. PMID 21671015. S2CID 19222468.
Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, et al. (July 2013). "LMTK3 is implicated in endocrine resistance via multiple signaling pathways". Oncogene. 32 (28): 3371–3380. doi:10.1038/onc.2012.343. PMID 22869149.
Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, et al. (June 2018). "LMTK3 confers chemo-resistance in breast cancer". Oncogene. 37 (23): 3113–3130. doi:10.1038/s41388-018-0197-0. PMC 5992129. PMID 29540829.
Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, et al. (June 2014). "The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁". Science Signaling. 7 (330): ra58. doi:10.1126/scisignal.2005170. PMID 24939894. S2CID 7831460.
Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, et al. (August 2015). "LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer". Cell Reports. 12 (5): 837–849. doi:10.1016/j.celrep.2015.06.073. hdl:10044/1/33933. PMID 26212333.
Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, et al. (November 2020). "The structure-function relationship of oncogenic LMTK3". Science Advances. 6 (46) eabc3099. Bibcode:2020SciA....6.3099D. doi:10.1126/sciadv.abc3099. PMC 7673765. PMID 33188023.
Agnarelli A, Lauer Betrán A, Papakyriakou A, Vella V, Samuels M, Papanastasopoulos P, et al. (January 2023). "The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor". International Journal of Molecular Sciences. 24 (1): 865. doi:10.3390/ijms24010865. PMC 9821308. PMID 36614307.

ensembl.org (Global: 1,626^th place; English: 1,007^th place)

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000142235 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000062044 – Ensembl, May 2017

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, et al. (August 2015). "LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer". Cell Reports. 12 (5): 837–849. doi:10.1016/j.celrep.2015.06.073. hdl:10044/1/33933. PMID 26212333.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, et al. (November 2020). "The structure-function relationship of oncogenic LMTK3". Science Advances. 6 (46) eabc3099. Bibcode:2020SciA....6.3099D. doi:10.1126/sciadv.abc3099. PMC 7673765. PMID 33188023.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Ditsiou A, Gagliano T, Samuels M, Vella V, Tolias C, Giamas G (September 2021). "The multifaceted role of lemur tyrosine kinase 3 in health and disease". Open Biology. 11 (9) 210218. doi:10.1098/rsob.210218. PMC 8478525. PMID 34582708.
Wendler F, Purice TM, Simon T, Stebbing J, Giamas G (September 2021). "The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis" (PDF). Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (9) 165372. doi:10.1016/j.bbadis.2018.12.023. PMID 30597196.
Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D, et al. (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID 21602804. S2CID 5279914.
Fazi B, Felsani A, Grassi L, Moles A, D'Andrea D, Toschi N, et al. (September 2015). "The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors". Oncotarget. 6 (26): 22526–22552. doi:10.18632/oncotarget.4151. PMC 4673180. PMID 26188123.
Xu Z, Qi X, Zhang X, Yu L (May 2014). "Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer". Tumour Biology. 35 (5): 5007–5011. doi:10.1007/s13277-014-1660-3. PMID 24510346. S2CID 14656556.
Lu L, Yuan X, Zhang Q, Zhang H, Shen B (April 2017). "LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer". Molecular Medicine Reports. 15 (4): 2015–2022. doi:10.3892/mmr.2017.6262. PMC 5364963. PMID 28260052.
Jiang T, Lu X, Yang F, Wang M, Yang H, Xing N (October 2020). "LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway". FEBS Open Bio. 10 (10): 2107–2121. doi:10.1002/2211-5463.12964. PMC 7530379. PMID 32865871.
Kawa S, Fujimoto J, Tezuka T, Nakazawa T, Yamamoto T (March 2004). "Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling". Genes to Cells. 9 (3): 219–232. doi:10.1111/j.1356-9597.2004.00714.x. PMID 15005709.
Inoue T, Hoshina N, Nakazawa T, Kiyama Y, Kobayashi S, Abe T, et al. (April 2014). "LMTK3 deficiency causes pronounced locomotor hyperactivity and impairs endocytic trafficking". The Journal of Neuroscience. 34 (17): 5927–5937. doi:10.1523/JNEUROSCI.1621-13.2014. PMC 6608282. PMID 24760852.
Montrose K, Kobayashi S, Manabe T, Yamamoto T (August 2019). "Lmtk3-KO Mice Display a Range of Behavioral Abnormalities and Have an Impairment in GluA1 Trafficking". Neuroscience. 414: 154–167. doi:10.1016/j.neuroscience.2019.06.033. PMID 31310731. S2CID 195937172.
Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, et al. (April 2012). "LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome". Breast Cancer Research and Treatment. 132 (2): 537–544. doi:10.1007/s10549-011-1622-z. PMID 21671015. S2CID 19222468.
Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, et al. (July 2013). "LMTK3 is implicated in endocrine resistance via multiple signaling pathways". Oncogene. 32 (28): 3371–3380. doi:10.1038/onc.2012.343. PMID 22869149.
Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, et al. (June 2018). "LMTK3 confers chemo-resistance in breast cancer". Oncogene. 37 (23): 3113–3130. doi:10.1038/s41388-018-0197-0. PMC 5992129. PMID 29540829.
Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, et al. (June 2014). "The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁". Science Signaling. 7 (330): ra58. doi:10.1126/scisignal.2005170. PMID 24939894. S2CID 7831460.
Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, et al. (August 2015). "LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer". Cell Reports. 12 (5): 837–849. doi:10.1016/j.celrep.2015.06.073. hdl:10044/1/33933. PMID 26212333.
Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, et al. (November 2020). "The structure-function relationship of oncogenic LMTK3". Science Advances. 6 (46) eabc3099. Bibcode:2020SciA....6.3099D. doi:10.1126/sciadv.abc3099. PMC 7673765. PMID 33188023.
Agnarelli A, Lauer Betrán A, Papakyriakou A, Vella V, Samuels M, Papanastasopoulos P, et al. (January 2023). "The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor". International Journal of Molecular Sciences. 24 (1): 865. doi:10.3390/ijms24010865. PMC 9821308. PMID 36614307.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Ditsiou A, Gagliano T, Samuels M, Vella V, Tolias C, Giamas G (September 2021). "The multifaceted role of lemur tyrosine kinase 3 in health and disease". Open Biology. 11 (9) 210218. doi:10.1098/rsob.210218. PMC 8478525. PMID 34582708.
Fazi B, Felsani A, Grassi L, Moles A, D'Andrea D, Toschi N, et al. (September 2015). "The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors". Oncotarget. 6 (26): 22526–22552. doi:10.18632/oncotarget.4151. PMC 4673180. PMID 26188123.
Lu L, Yuan X, Zhang Q, Zhang H, Shen B (April 2017). "LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer". Molecular Medicine Reports. 15 (4): 2015–2022. doi:10.3892/mmr.2017.6262. PMC 5364963. PMID 28260052.
Jiang T, Lu X, Yang F, Wang M, Yang H, Xing N (October 2020). "LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway". FEBS Open Bio. 10 (10): 2107–2121. doi:10.1002/2211-5463.12964. PMC 7530379. PMID 32865871.
Inoue T, Hoshina N, Nakazawa T, Kiyama Y, Kobayashi S, Abe T, et al. (April 2014). "LMTK3 deficiency causes pronounced locomotor hyperactivity and impairs endocytic trafficking". The Journal of Neuroscience. 34 (17): 5927–5937. doi:10.1523/JNEUROSCI.1621-13.2014. PMC 6608282. PMID 24760852.
Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, et al. (June 2018). "LMTK3 confers chemo-resistance in breast cancer". Oncogene. 37 (23): 3113–3130. doi:10.1038/s41388-018-0197-0. PMC 5992129. PMID 29540829.
Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, et al. (November 2020). "The structure-function relationship of oncogenic LMTK3". Science Advances. 6 (46) eabc3099. Bibcode:2020SciA....6.3099D. doi:10.1126/sciadv.abc3099. PMC 7673765. PMID 33188023.
Agnarelli A, Lauer Betrán A, Papakyriakou A, Vella V, Samuels M, Papanastasopoulos P, et al. (January 2023). "The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor". International Journal of Molecular Sciences. 24 (1): 865. doi:10.3390/ijms24010865. PMC 9821308. PMID 36614307.

nii.ac.jp (Global: 304^th place; English: 1,952^nd place)

oist.repo.nii.ac.jp

Montrose K, Kobayashi S, Manabe T, Yamamoto T (August 2019). "Lmtk3-KO Mice Display a Range of Behavioral Abnormalities and Have an Impairment in GluA1 Trafficking". Neuroscience. 414: 154–167. doi:10.1016/j.neuroscience.2019.06.033. PMID 31310731. S2CID 195937172.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D, et al. (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID 21602804. S2CID 5279914.
Xu Z, Qi X, Zhang X, Yu L (May 2014). "Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer". Tumour Biology. 35 (5): 5007–5011. doi:10.1007/s13277-014-1660-3. PMID 24510346. S2CID 14656556.
Montrose K, Kobayashi S, Manabe T, Yamamoto T (August 2019). "Lmtk3-KO Mice Display a Range of Behavioral Abnormalities and Have an Impairment in GluA1 Trafficking". Neuroscience. 414: 154–167. doi:10.1016/j.neuroscience.2019.06.033. PMID 31310731. S2CID 195937172.
Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, et al. (April 2012). "LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome". Breast Cancer Research and Treatment. 132 (2): 537–544. doi:10.1007/s10549-011-1622-z. PMID 21671015. S2CID 19222468.
Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, et al. (June 2014). "The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁". Science Signaling. 7 (330): ra58. doi:10.1126/scisignal.2005170. PMID 24939894. S2CID 7831460.

sussex.ac.uk (Global: 6,651^st place; English: 4,464^th place)

sro.sussex.ac.uk

Wendler F, Purice TM, Simon T, Stebbing J, Giamas G (September 2021). "The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis" (PDF). Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (9) 165372. doi:10.1016/j.bbadis.2018.12.023. PMID 30597196.

worktribe.com (Global: low place; English: low place)

nottingham-repository.worktribe.com

Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, et al. (June 2014). "The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁". Science Signaling. 7 (330): ra58. doi:10.1126/scisignal.2005170. PMID 24939894. S2CID 7831460.